Trials / Completed
CompletedNCT04119960
Clinical Validation of InferRead Lung CT.AI
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (actual)
- Sponsor
- Infervision · Industry
- Sex
- All
- Age
- 55 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
Lung cancer is the second most common cause of cancer-related death in men and women. Early pulmonary nodule screening is an effective means to prevent lung cancer, which is no less important than the diagnosis and treatment of lung cancer. Early lung cancer screening has been investigated and applied as a medical practice. InferRead Lung CT.AI by Infervision is a dedicated post processing application that generates CADe marks as an overlay on the original CT series intended to aid the radiologist in the detection of pulmonary nodules. This study was designed to evaluate radiologists' performance in detecting actionable nodules on chest CT when aided by InferRead.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Aided read with InferRead Lung CT.AI | Radiologists read chest CT scans with the aid of InferRead Lung CT.AI |
Timeline
- Start date
- 2019-01-10
- Primary completion
- 2019-06-01
- Completion
- 2019-10-30
- First posted
- 2019-10-09
- Last updated
- 2020-07-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04119960. Inclusion in this directory is not an endorsement.